Understand the source comparison
[Peptide Types for Joint Health]: Research Comparison
Hydrolyzed Collagen (oral) Fibroblast signaling via proline-hydroxyproline dipeptides; indirect collagen synthesis 10–15g daily oral Strong (15+ RCTs, meta-analyses available) Best-supported option for mild-to-moderate OA; requires 8–12 weeks; effect size mode
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Hydrolyzed Collagen (oral)
- Fibroblast signaling via proline-hydroxyproline dipeptides; indirect collagen synthesis
- 10–15g daily oral
- Strong (15+ RCTs, meta-analyses available)
- Best-supported option for mild-to-moderate OA; requires 8–12 weeks; effect size modest (VAS reduction 1.5–2.5 points)
- BPC-157 (injectable)
- Direct anti-inflammatory (IL-6, TNF-alpha downregulation); angiogenesis promotion
- 250–500mcg daily SC
- Moderate (extensive animal data, limited human trials)
- Strongest preclinical evidence for soft tissue repair; regulatory status limits widespread use
- TB-500 (injectable)
- Thymosin beta-4 fragment; promotes cell migration, reduces fibrosis
- 2–5mg weekly SC
- Moderate (animal models robust, human data sparse)
- Used primarily in veterinary and research contexts; human evidence largely anecdotal
- Matrixyl (topical/oral)
- Chondrocyte proliferation; ECM component synthesis
- 500mg–1g daily oral or topical
- Weak (small pilot studies, in vitro data)
- Promising in vitro but insufficient human joint-specific trials; more data needed
- MK-677 (oral)
- GH secretagogue; elevates IGF-1 (indirect collagen/bone support)
- 10–25mg daily oral
- Moderate (endocrine effects well-documented; joint-specific outcomes limited)
- Indirect mechanism; best for systemic musculoskeletal support rather than targeted joint repair
- The comparison above reflects published evidence as of 2026—peptide research evolves rapidly, and emerging compounds may shift these assessments within 2–3 years.